Clinical trial
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
NCT06178211 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
- Lead sponsor
- Shanghai Chest Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 31, 2023
- Completion date
- November 30, 2026
- Enrollment
- 36 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.